SlideShare una empresa de Scribd logo
1 de 16
National HIDTA Program
High Intensity Drug Trafficking Areas
Presenters:
• Shannon Kelly, MA, Deputy Director, National HIDTA
Program, Office of National Drug Control Policy
• James F. Bohn, JD, Director, Wisconsin HIDTA
• Jack Killorin, Director, Atlanta-Carolinas HIDTA
Federal Track
Moderator: Sarah T. Melton, PharmD, Associate Professor of
Pharmacy Practice, Gatton College of Pharmacy, East Tennessee
State University
Learning Objectives
1. Explain the HIDTA program.
2. Identify potential areas for collaboration in
drug-trafficking responses in various regions
of the country.
3. Describe innovative HIDTA operations and
initiatives.
High Intensity Drug Trafficking
Areas (HIDTA)
March 30, 2016
Office of National Drug Control Policy
• Part of the Executive Office of the President
• Coordinates drug-control activities and related funding across the
Federal Government
• Produces the annual National Drug Control Strategy
• Administers two national grant programs: High Intensity Drug
Trafficking Areas (HIDTA) and Drug-Free Communities
• Provides assistance to Federal, state, local, and tribal law enforcement agencies
in critical drug trafficking regions of the United States.
• Fiscal Year 2016 funding level of $250 million.
• 28 regional HIDTAs in 48 states, Puerto Rico, the U.S. Virgin Islands, and
Washington, D.C.
• Achieves its purpose by:
– Facilitates cooperation among Federal, state, local, and tribal law
enforcement to share intelligence and implement enforcement activities.
– Supports coordinated law enforcement strategies to reduce the supply of
illegal drugs in the United States.
High Intensity Drug Trafficking Areas
(HIDTA) Program and Purpose
• The HIDTA program is not an agency: it is a partnership
of Federal, state, local, and tribal agencies
• Each HIDTA program has an executive board that:
– Has an equal number of Federal, state, and local members
– Has discretion to decide what is funded and where funds are
spent
– Identifies regional and local threats
– Develops a strategy to address threats
– Requests funding for HIDTA initiatives to implement the
strategy
– Measures and reports performance
– Hires a HIDTA director to administer HIDTA functions
HIDTA Program Structure
HIDTA requirements:
– Area is a significant center of illegal drug production,
manufacturing, importation, or distribution;
– State, local, and tribal law enforcement agencies have
committed resources to respond to drug trafficking in the
area, this indicates willingness to address the issue;
– Drug-related activities in the area have a significant harmful
impact in the area and in other areas of the country; and
– Federal resources are necessary to respond adequately to drug
related activities in the area.
Criteria for HIDTA Designation
HIDTA Program Accomplishments
In 2015, the HIDTA Program:
• 2,500 drug trafficking or money laundering organizations disrupted
or dismantled.
• $18.6 billion (wholesale) removed from the marketplace .
• 36,000 fugitives apprehended.
• 31,000 leads provided to law enforcement agencies across the
country.
• 98,000 officers, agents, analysts, and support staff trained on drug-
related topics.
HIDTA Program Participants
The HIDTA Program brings together:
• 737 initiatives in 28 regional programs
• 7,400 Federal agents and analysts
• 15,700 state, local, and tribal officers, analysts, and other
representatives
• 500 agencies, including public health agencies to coordinate and
collaborate with HIDTA task forces
• 59 intelligence and investigative support centers/information sharing
initiatives
The HIDTA Program employs a three-pronged approach to
address the trafficking and use of heroin and other opioids:
– Law enforcement initiatives and task forces that target the
diversion and trafficking of heroin, fentanyl and other opioids
– Public health and prevention efforts to reduce heroin and
nonmedical opioid use and its consequences
– HIDTA-sponsored law enforcement training courses that
address heroin and other opioid trafficking
HIDTA Program Efforts to Address the
Nation’s Heroin & Opioid Epidemic
HIDTA Law Enforcement Efforts
• Targeting large-scale heroin trafficking – Southwest Border
HIDTA – New Mexico Region
• Dismantling a heroin- and fentanyl-trafficking organization –
New England HIDTA
• Dismantling a multi-state oxycodone trafficking organization –
Northwest HIDTA
• Dismantling a Dilaudid-trafficking organization – Gulf Coast
HIDTA
HIDTA Public Health & Prevention Efforts
• Naloxone use by law enforcement officers – Multiple regional
HIDTA programs
• No More NAS (Neonatal Abstinence Syndrome) Initiative –
Appalachia HIDTA
• Snohomish County Opiate Project – Northwest HIDTA
• Heroin: Not Even Once Initiative – Midwest HIDTA
• SCOPE of Pain Initiative – New England HIDTA
• Safe & Sound Initiative – Wisconsin HIDTA
HIDTA Training Efforts
Each year, regional HIDTA programs sponsor training courses that
address the diversion and use of heroin and other opioids.
Examples include:
• HIDTA Heroin Symposium – Philadelphia/Camden HIDTA
• Meeting the Opiate Challenge – Wisconsin HIDTA
• Investigating Heroin-Trafficking Organizations – Ohio HIDTA
• Investigating Prescription Drug Crimes – New England HIDTA
• Mexican Drug Trafficking Organizations and Heroin Awareness
for Law Enforcement – Los Angeles HIDTA
HIDTA Heroin Response Strategy
• ONDCP has committed $2.5 million in HIDTA funds to develop a
strategy to respond to the Nation’s heroin epidemic.
• Three main goals:
– Enhance the Drug Intelligence Officer Network
– Foster critical public health-public safety partnerships through a
State of the Region Symposium
– Educate and raise awareness through an online initiative and
further prevention efforts in collaboration with the Partnership
for Drug-Free Kids
Contact Information
Michael K. Gottlieb
Director, National HIDTA Program
Assistant Deputy Director, Office of National Drug Control Policy
(202) 395-4868
mgottlieb@ondcp.eop.gov
Shannon Kelly
Deputy Director, National HIDTA Program
(202) 395-5872
skelly@ondcp.eop.gov

Más contenido relacionado

La actualidad más candente

Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonRx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonOPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliOPUNITE
 
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdevaRx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdevaOPUNITE
 
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchRx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchOPUNITE
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceOPUNITE
 
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylorRx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylorOPUNITE
 
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriendRx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriendOPUNITE
 
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyWeb only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyOPUNITE
 
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverRx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverOPUNITE
 
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbinsRx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbinsOPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
 
Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynoteOPUNITE
 
Rx16 pharma tues_200_1_kelly_2ream_3shanehsaz
Rx16 pharma tues_200_1_kelly_2ream_3shanehsazRx16 pharma tues_200_1_kelly_2ream_3shanehsaz
Rx16 pharma tues_200_1_kelly_2ream_3shanehsazOPUNITE
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_finalOPUNITE
 
Rx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gormanRx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gormanOPUNITE
 
Rx16 federal visionsession_200
Rx16 federal visionsession_200Rx16 federal visionsession_200
Rx16 federal visionsession_200OPUNITE
 
Rx16 workshop 200_group_ppt
Rx16 workshop 200_group_pptRx16 workshop 200_group_ppt
Rx16 workshop 200_group_pptOPUNITE
 
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armaganRx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armaganOPUNITE
 
Rx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williamsRx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williamsOPUNITE
 

La actualidad más candente (20)

Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonRx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdevaRx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
 
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchRx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
 
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylorRx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
 
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriendRx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
 
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyWeb only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
 
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverRx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
 
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbinsRx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Rx16 pharma tues_200_1_kelly_2ream_3shanehsaz
Rx16 pharma tues_200_1_kelly_2ream_3shanehsazRx16 pharma tues_200_1_kelly_2ream_3shanehsaz
Rx16 pharma tues_200_1_kelly_2ream_3shanehsaz
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Rx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gormanRx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gorman
 
Rx16 federal visionsession_200
Rx16 federal visionsession_200Rx16 federal visionsession_200
Rx16 federal visionsession_200
 
Rx16 workshop 200_group_ppt
Rx16 workshop 200_group_pptRx16 workshop 200_group_ppt
Rx16 workshop 200_group_ppt
 
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armaganRx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
 
Rx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williamsRx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williams
 

Destacado

Could You Get Justice In The Middle Ages
Could You Get Justice In The Middle AgesCould You Get Justice In The Middle Ages
Could You Get Justice In The Middle AgesDHUMPHREYS
 
Middle East Punishment Ppt2
Middle East Punishment Ppt2Middle East Punishment Ppt2
Middle East Punishment Ppt2mountianview
 
02. آگهی نامه نمونه - قالب بندی مطالعات و نتایج تحقیق
02. آگهی نامه نمونه - قالب بندی مطالعات و نتایج تحقیق02. آگهی نامه نمونه - قالب بندی مطالعات و نتایج تحقیق
02. آگهی نامه نمونه - قالب بندی مطالعات و نتایج تحقیقShahram Honarmayeh
 
Human Trafficking in the Middle East
Human Trafficking in the Middle EastHuman Trafficking in the Middle East
Human Trafficking in the Middle EastBilhami
 
Humantraff
HumantraffHumantraff
Humantraffdwig00
 
Black & Veatch Energy Market Perspective: 2015 Outlook
Black & Veatch Energy Market Perspective: 2015 OutlookBlack & Veatch Energy Market Perspective: 2015 Outlook
Black & Veatch Energy Market Perspective: 2015 OutlookBlack & Veatch
 
Human Trafficking And Globalization
Human Trafficking And GlobalizationHuman Trafficking And Globalization
Human Trafficking And Globalizationmulvey.laura
 
INTERPOL and Environmental Crimes
INTERPOL and Environmental CrimesINTERPOL and Environmental Crimes
INTERPOL and Environmental CrimesUNEP OzonAction
 
Rx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pewRx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pewOPUNITE
 
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerOPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_groupOPUNITE
 
Rx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2wallerRx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2wallerOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Web only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2badaWeb only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2badaOPUNITE
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyOPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattOPUNITE
 
Cyber Crime Challenges in the Middle East
Cyber Crime Challenges in the Middle EastCyber Crime Challenges in the Middle East
Cyber Crime Challenges in the Middle EastMohamed N. El-Guindy
 

Destacado (19)

Could You Get Justice In The Middle Ages
Could You Get Justice In The Middle AgesCould You Get Justice In The Middle Ages
Could You Get Justice In The Middle Ages
 
Middle East Punishment Ppt2
Middle East Punishment Ppt2Middle East Punishment Ppt2
Middle East Punishment Ppt2
 
02. آگهی نامه نمونه - قالب بندی مطالعات و نتایج تحقیق
02. آگهی نامه نمونه - قالب بندی مطالعات و نتایج تحقیق02. آگهی نامه نمونه - قالب بندی مطالعات و نتایج تحقیق
02. آگهی نامه نمونه - قالب بندی مطالعات و نتایج تحقیق
 
Human Trafficking in the Middle East
Human Trafficking in the Middle EastHuman Trafficking in the Middle East
Human Trafficking in the Middle East
 
Humantraff
HumantraffHumantraff
Humantraff
 
Black & Veatch Energy Market Perspective: 2015 Outlook
Black & Veatch Energy Market Perspective: 2015 OutlookBlack & Veatch Energy Market Perspective: 2015 Outlook
Black & Veatch Energy Market Perspective: 2015 Outlook
 
Interpol
InterpolInterpol
Interpol
 
Black Market | Eonomics
Black Market | EonomicsBlack Market | Eonomics
Black Market | Eonomics
 
Human Trafficking And Globalization
Human Trafficking And GlobalizationHuman Trafficking And Globalization
Human Trafficking And Globalization
 
INTERPOL and Environmental Crimes
INTERPOL and Environmental CrimesINTERPOL and Environmental Crimes
INTERPOL and Environmental Crimes
 
Rx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pewRx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pew
 
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 
Rx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2wallerRx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2waller
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Web only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2badaWeb only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2bada
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Cyber Crime Challenges in the Middle East
Cyber Crime Challenges in the Middle EastCyber Crime Challenges in the Middle East
Cyber Crime Challenges in the Middle East
 

Similar a Rx16 federal wed_1230_1_kelly_2bohn-killorin

Using Public and Private Policies to Recalim Community Festivals for Families
Using Public and Private Policies to Recalim Community Festivals for FamiliesUsing Public and Private Policies to Recalim Community Festivals for Families
Using Public and Private Policies to Recalim Community Festivals for FamiliesLeticia Chavez
 
W8 - Community Mobilization: How to Get Community Partners Involved in HIV Pr...
W8 - Community Mobilization: How to Get Community Partners Involved in HIV Pr...W8 - Community Mobilization: How to Get Community Partners Involved in HIV Pr...
W8 - Community Mobilization: How to Get Community Partners Involved in HIV Pr...NYC Department of Health and Mental Hygiene
 
Rx15 vision wed_200_oig
Rx15 vision wed_200_oigRx15 vision wed_200_oig
Rx15 vision wed_200_oigOPUNITE
 
Tuesday partnership
Tuesday partnershipTuesday partnership
Tuesday partnershipOPUNITE
 
Sherry Green
Sherry GreenSherry Green
Sherry GreenOPUNITE
 
Substance Abuse Ionia, Michigan
Substance Abuse Ionia, MichiganSubstance Abuse Ionia, Michigan
Substance Abuse Ionia, Michiganrecoveryrestart2
 
Prescription drugs first do no harm update
Prescription drugs first do no harm updatePrescription drugs first do no harm update
Prescription drugs first do no harm updateNNAPF_web
 
DEA Presentation
DEA PresentationDEA Presentation
DEA Presentationbiggame8
 
3rd National Alcohol Forum Conference
3rd National Alcohol Forum Conference 3rd National Alcohol Forum Conference
3rd National Alcohol Forum Conference AlcoholForum.org
 
Susan Shepherd - Panel - Alternatives to the War on Drugs
Susan Shepherd - Panel - Alternatives to the War on DrugsSusan Shepherd - Panel - Alternatives to the War on Drugs
Susan Shepherd - Panel - Alternatives to the War on DrugsCSSDPUofT
 
Wed vs cadca
Wed vs cadcaWed vs cadca
Wed vs cadcaOPUNITE
 
Be aware, take action: fight counterfeits, keep patients safer
Be aware, take action: fight counterfeits, keep patients saferBe aware, take action: fight counterfeits, keep patients safer
Be aware, take action: fight counterfeits, keep patients saferThe Partnership For Safe Medicines
 
Embedding quality improvement in community health in Africa and Asia : What i...
Embedding quality improvement in community health in Africa and Asia: What i...Embedding quality improvement in community health in Africa and Asia: What i...
Embedding quality improvement in community health in Africa and Asia : What i...REACHOUTCONSORTIUMSLIDES
 
Health Impact Assessment and Health in All Policies
Health Impact Assessment and Health in All PoliciesHealth Impact Assessment and Health in All Policies
Health Impact Assessment and Health in All PoliciesSandra Whitehead
 
2017 Annual report summary-en
2017 Annual report summary-en2017 Annual report summary-en
2017 Annual report summary-enDianovaint
 
The Campaign to Fix the Debt Overview
The Campaign to Fix the Debt OverviewThe Campaign to Fix the Debt Overview
The Campaign to Fix the Debt OverviewFix the Debt Campaign
 
Preparing for the nfm+crg 12th dec 2013
Preparing for the nfm+crg 12th dec 2013Preparing for the nfm+crg 12th dec 2013
Preparing for the nfm+crg 12th dec 2013clac.cab
 

Similar a Rx16 federal wed_1230_1_kelly_2bohn-killorin (20)

Using Public and Private Policies to Recalim Community Festivals for Families
Using Public and Private Policies to Recalim Community Festivals for FamiliesUsing Public and Private Policies to Recalim Community Festivals for Families
Using Public and Private Policies to Recalim Community Festivals for Families
 
W8 - Community Mobilization: How to Get Community Partners Involved in HIV Pr...
W8 - Community Mobilization: How to Get Community Partners Involved in HIV Pr...W8 - Community Mobilization: How to Get Community Partners Involved in HIV Pr...
W8 - Community Mobilization: How to Get Community Partners Involved in HIV Pr...
 
Rx15 vision wed_200_oig
Rx15 vision wed_200_oigRx15 vision wed_200_oig
Rx15 vision wed_200_oig
 
Ngo's1 3
Ngo's1 3Ngo's1 3
Ngo's1 3
 
Tuesday partnership
Tuesday partnershipTuesday partnership
Tuesday partnership
 
Office Of Substance Abuse Prevention2
Office Of Substance Abuse Prevention2Office Of Substance Abuse Prevention2
Office Of Substance Abuse Prevention2
 
Sherry Green
Sherry GreenSherry Green
Sherry Green
 
Substance Abuse Ionia, Michigan
Substance Abuse Ionia, MichiganSubstance Abuse Ionia, Michigan
Substance Abuse Ionia, Michigan
 
DAT reform-2
DAT reform-2DAT reform-2
DAT reform-2
 
Prescription drugs first do no harm update
Prescription drugs first do no harm updatePrescription drugs first do no harm update
Prescription drugs first do no harm update
 
DEA Presentation
DEA PresentationDEA Presentation
DEA Presentation
 
3rd National Alcohol Forum Conference
3rd National Alcohol Forum Conference 3rd National Alcohol Forum Conference
3rd National Alcohol Forum Conference
 
Susan Shepherd - Panel - Alternatives to the War on Drugs
Susan Shepherd - Panel - Alternatives to the War on DrugsSusan Shepherd - Panel - Alternatives to the War on Drugs
Susan Shepherd - Panel - Alternatives to the War on Drugs
 
Wed vs cadca
Wed vs cadcaWed vs cadca
Wed vs cadca
 
Be aware, take action: fight counterfeits, keep patients safer
Be aware, take action: fight counterfeits, keep patients saferBe aware, take action: fight counterfeits, keep patients safer
Be aware, take action: fight counterfeits, keep patients safer
 
Embedding quality improvement in community health in Africa and Asia : What i...
Embedding quality improvement in community health in Africa and Asia: What i...Embedding quality improvement in community health in Africa and Asia: What i...
Embedding quality improvement in community health in Africa and Asia : What i...
 
Health Impact Assessment and Health in All Policies
Health Impact Assessment and Health in All PoliciesHealth Impact Assessment and Health in All Policies
Health Impact Assessment and Health in All Policies
 
2017 Annual report summary-en
2017 Annual report summary-en2017 Annual report summary-en
2017 Annual report summary-en
 
The Campaign to Fix the Debt Overview
The Campaign to Fix the Debt OverviewThe Campaign to Fix the Debt Overview
The Campaign to Fix the Debt Overview
 
Preparing for the nfm+crg 12th dec 2013
Preparing for the nfm+crg 12th dec 2013Preparing for the nfm+crg 12th dec 2013
Preparing for the nfm+crg 12th dec 2013
 

Más de OPUNITE

Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynoteOPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynoteOPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerOPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioOPUNITE
 
Rx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenRx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenOPUNITE
 
Web only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haasWeb only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haasOPUNITE
 

Más de OPUNITE (9)

Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
 
Rx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenRx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2green
 
Web only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haasWeb only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haas
 

Último

METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxDr.Nusrat Tariq
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...saminamagar
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?bkling
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 

Último (20)

METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 

Rx16 federal wed_1230_1_kelly_2bohn-killorin

  • 1. National HIDTA Program High Intensity Drug Trafficking Areas Presenters: • Shannon Kelly, MA, Deputy Director, National HIDTA Program, Office of National Drug Control Policy • James F. Bohn, JD, Director, Wisconsin HIDTA • Jack Killorin, Director, Atlanta-Carolinas HIDTA Federal Track Moderator: Sarah T. Melton, PharmD, Associate Professor of Pharmacy Practice, Gatton College of Pharmacy, East Tennessee State University
  • 2. Learning Objectives 1. Explain the HIDTA program. 2. Identify potential areas for collaboration in drug-trafficking responses in various regions of the country. 3. Describe innovative HIDTA operations and initiatives.
  • 3. High Intensity Drug Trafficking Areas (HIDTA) March 30, 2016
  • 4. Office of National Drug Control Policy • Part of the Executive Office of the President • Coordinates drug-control activities and related funding across the Federal Government • Produces the annual National Drug Control Strategy • Administers two national grant programs: High Intensity Drug Trafficking Areas (HIDTA) and Drug-Free Communities
  • 5. • Provides assistance to Federal, state, local, and tribal law enforcement agencies in critical drug trafficking regions of the United States. • Fiscal Year 2016 funding level of $250 million. • 28 regional HIDTAs in 48 states, Puerto Rico, the U.S. Virgin Islands, and Washington, D.C. • Achieves its purpose by: – Facilitates cooperation among Federal, state, local, and tribal law enforcement to share intelligence and implement enforcement activities. – Supports coordinated law enforcement strategies to reduce the supply of illegal drugs in the United States. High Intensity Drug Trafficking Areas (HIDTA) Program and Purpose
  • 6.
  • 7. • The HIDTA program is not an agency: it is a partnership of Federal, state, local, and tribal agencies • Each HIDTA program has an executive board that: – Has an equal number of Federal, state, and local members – Has discretion to decide what is funded and where funds are spent – Identifies regional and local threats – Develops a strategy to address threats – Requests funding for HIDTA initiatives to implement the strategy – Measures and reports performance – Hires a HIDTA director to administer HIDTA functions HIDTA Program Structure
  • 8. HIDTA requirements: – Area is a significant center of illegal drug production, manufacturing, importation, or distribution; – State, local, and tribal law enforcement agencies have committed resources to respond to drug trafficking in the area, this indicates willingness to address the issue; – Drug-related activities in the area have a significant harmful impact in the area and in other areas of the country; and – Federal resources are necessary to respond adequately to drug related activities in the area. Criteria for HIDTA Designation
  • 9. HIDTA Program Accomplishments In 2015, the HIDTA Program: • 2,500 drug trafficking or money laundering organizations disrupted or dismantled. • $18.6 billion (wholesale) removed from the marketplace . • 36,000 fugitives apprehended. • 31,000 leads provided to law enforcement agencies across the country. • 98,000 officers, agents, analysts, and support staff trained on drug- related topics.
  • 10. HIDTA Program Participants The HIDTA Program brings together: • 737 initiatives in 28 regional programs • 7,400 Federal agents and analysts • 15,700 state, local, and tribal officers, analysts, and other representatives • 500 agencies, including public health agencies to coordinate and collaborate with HIDTA task forces • 59 intelligence and investigative support centers/information sharing initiatives
  • 11. The HIDTA Program employs a three-pronged approach to address the trafficking and use of heroin and other opioids: – Law enforcement initiatives and task forces that target the diversion and trafficking of heroin, fentanyl and other opioids – Public health and prevention efforts to reduce heroin and nonmedical opioid use and its consequences – HIDTA-sponsored law enforcement training courses that address heroin and other opioid trafficking HIDTA Program Efforts to Address the Nation’s Heroin & Opioid Epidemic
  • 12. HIDTA Law Enforcement Efforts • Targeting large-scale heroin trafficking – Southwest Border HIDTA – New Mexico Region • Dismantling a heroin- and fentanyl-trafficking organization – New England HIDTA • Dismantling a multi-state oxycodone trafficking organization – Northwest HIDTA • Dismantling a Dilaudid-trafficking organization – Gulf Coast HIDTA
  • 13. HIDTA Public Health & Prevention Efforts • Naloxone use by law enforcement officers – Multiple regional HIDTA programs • No More NAS (Neonatal Abstinence Syndrome) Initiative – Appalachia HIDTA • Snohomish County Opiate Project – Northwest HIDTA • Heroin: Not Even Once Initiative – Midwest HIDTA • SCOPE of Pain Initiative – New England HIDTA • Safe & Sound Initiative – Wisconsin HIDTA
  • 14. HIDTA Training Efforts Each year, regional HIDTA programs sponsor training courses that address the diversion and use of heroin and other opioids. Examples include: • HIDTA Heroin Symposium – Philadelphia/Camden HIDTA • Meeting the Opiate Challenge – Wisconsin HIDTA • Investigating Heroin-Trafficking Organizations – Ohio HIDTA • Investigating Prescription Drug Crimes – New England HIDTA • Mexican Drug Trafficking Organizations and Heroin Awareness for Law Enforcement – Los Angeles HIDTA
  • 15. HIDTA Heroin Response Strategy • ONDCP has committed $2.5 million in HIDTA funds to develop a strategy to respond to the Nation’s heroin epidemic. • Three main goals: – Enhance the Drug Intelligence Officer Network – Foster critical public health-public safety partnerships through a State of the Region Symposium – Educate and raise awareness through an online initiative and further prevention efforts in collaboration with the Partnership for Drug-Free Kids
  • 16. Contact Information Michael K. Gottlieb Director, National HIDTA Program Assistant Deputy Director, Office of National Drug Control Policy (202) 395-4868 mgottlieb@ondcp.eop.gov Shannon Kelly Deputy Director, National HIDTA Program (202) 395-5872 skelly@ondcp.eop.gov

Notas del editor

  1. Southwest Border HIDTA – New Mexico Region – Region 1 Task Force dismantled a DTO that trafficked large quantities of heroin in the southwestern United States. This task force dismantled an organization that used proceeds from multi-pound heroin sales to purchase local businesses that were then used to launder drug proceeds. Spin-off investigations conducted by the IRS and DEA are ongoing. New England HIDTA – The Southern New Hampshire HIDTA Task Force targeted, disrupted, and dismantled the largest regional drug trafficking organization transporting, processing, and distributing multi-kilogram quantities of heroin and fentanyl in the region.
  2. Naloxone Distribution - Multiple regional HIDTAs, including Appalachia, New England, Northwest, and Oregon-Idaho fund efforts to expand the use of naloxone by equipping law enforcement officers to carry this opioid reversal drug. No More NAS - In 2014, the Appalachia HIDTA launched its No More NAS (Neonatal Abstinence Syndrome) program. This partnership includes the HIDTA, the Knoxville Police Department, the Metropolitan Drug Commission, the Born Drug Free Tennessee campaign, Cherokee Health Systems, and the University of Tennessee College of Nursing. They are training local obstetrical and gynecological providers in eastern Tennessee to screen women of childbearing age for substance use by employing evidence-based screening tools. These screenings afford at-risk women an opportunity to receive counseling and access to treatment Snohomish County Opiate Project - The Project counters the alarming increase in opiate availability, use, and addiction in the county by providing training to law enforcement officers in the use of the naloxone overdose prevention kits and distributing the kits to law enforcement agencies and others across Snohomish County.